$599

J&J Investor Event Summary

J&J hosted their pharmaceutical business review and provided commentary on the Invokana boxed warning, CANVAS/R and CREDENCE, and their pipeline dual GLP-1/glucagon agonist from Hanmi.

This content is for Read Less members only.
Register
Already a member? Log in here